TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Key 2026 clinical milestones: The recurrent cSCC pivotal trial is nearing completion with last patient treatments expected imminently and topline data planned for H2 2026, while a GBM pilot safety ...
On Tuesday, March 10, 2026, PolyPid (NASDAQ:PYPD) presented at The Citizens Life Sciences Conference 2026, highlighting its strategic initiatives and future plans. The conference call underscored the ...
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally ...
PolyPid Ltd. misses on earnings expectations. Reported EPS is $-0.41 EPS, expectations were $-0.34. Operator: Greetings and welcome to PolyPid’s Fourth Quarter and Full Year 2025 Conference Call.
ATLANTA - Artivion, Inc. (NYSE:AORT), a $1.93 billion market cap medical device company whose shares have surged 31.86% over the past six months, announced new clinical data from two trials evaluating ...
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results